Differences in Spatial Memory Impairment in Mice after Oral D-Galactose Administration and Intraperitoneal Injection

BACKGROUND: The aging process can increase the incidence of dementia, such as spatial memory impairment to remember space, recognize shapes and distances. Research on dementia in mice was carried out by administering d-galactose through intraperitoneal injection, while oral d-galactose administration had not received enough attention. AIM: This study aims to prove the differences in the occurrence of spatial memory impairment in rats induced by d-galactose through two different routes, oral and intraperitoneal injection. METHODS: This study is an experimental study using a post- test control group design. The sample criteria were 20 male Wistar rats aged 12–14 weeks, weighing 200–300 g divided into two groups which are the oral and intraperitoneal injection. Spatial memory assessment based on spontaneous alternation using the Y-maze test was carried out at the end of week 8. RESULTS: In this study, the average spatial memory score after d-galactose administration in the injection group (51.572±4.388) was lower compared to the oral group (66.058±1.551). The Shapiro–Wilk normality test shows that the data are normally distributed with p > 0.05. Independent t-test showed a significant difference in the incidence of spatial memory disorders between the injection and oral groups with p = 0.010 (p < 0.05). CONCLUSION: The conclusion of this study is that d-galactose administration by oral route or intraperitoneal injection causes a decrease in spatial memory in mice. Spatial memory in the injection group was lower than in the oral group. This might be related to the decrease in synaptophysin in the hippocampus of mice due to d-galactose administration by intraperitoneal injection

INTERLEUKIN-1, INTERLEUKIN-6, AND ANTAGONIST INTERLEUKIN-1RECEPTOR AS MEMORY IMPAIRMENT RISK FACTOR IN COMPLEX PARTIAL EPILEPSY

Memory impairment is one of the most common adverse following epilepsy, particularly complexpartial epilepsy. Cytokines physiologically play an important role in memory impairment by preventing long term potentiation process in hypocampus. Several literatures have mentioned that IL-1, IL-6 and antagonist receptor IL-1Ra are crucial cytokines in complex partial epilepsy. This study aims to find out whether high level of IL-1 and IL-6 as well as low level of IL-1Ra might be risk factors of memory impairment in complex partial epilepsy patient. This was a case control study, enrolling 30 complex partial epilepsy patients with memory impairment as case group and 30 complex partial epilepsy patients without memory impairment as control group.In this study, it was obtained that the mean of IL-1β level in case group was significantly higher compared to the control (2.74 ± 4.36 vs. 0.42 ± 0.18 pg/ml, p = 0.007). The mean of IL-6 in case group was significantly higher compare to control (5.89 ± 6.32 vs. 2.34 ± 1.80 pg/ml, p = 0.006). The mean of IL-1Ra level of the case group was not significantly higher compared to the control (519.81 ± 262.64 vs. 413.28 ± 106.85, p = 0.767). By applying bivariate analysis, McNemar’s test, we observed that IL-1β with cut off point 0.63 pg/ml and OR = 70 is a risk factor of memory impairment in complex partial epilepsy indicated by p = 0.001. Similar result was also gained for IL-6 with cut off point 2.87 pg/ml and OR = 4.57 as a risk factor of memory impairment in complex partial epilepsy indicated by p = 0.007. Meanwhile, IL- 1Ra with cut off point 471 pg/ml and OR = 0.727 was not as a risk factor of memory impairment in complex partial epilepsy indicated by p = 0.573.It can be concluded that the high level of IL-1B and IL-6 were the risk factors of memory impairment in complex partial epilepsy patients. High level 1L-1B patient was 70 times higher risk of becoming memory impaired. High IL-6 patients will have the risk nearly 5 times higher. The low level of IL-1Ra does not as a risk factor in epilepsy patients for having the following memory impairment.</p

The Difference of Brainstem Auditory Evoked Potential Latency in Diabetic Patient with Good and Poor Glycemic Control

BACKGROUND: Diabetes mellitus (DM) is a metabolic disorder which may complicate other organs, including the nervous system. Literatures which discuss about DM complications in the peripheral nervous system are easy to find but not so many of the central nervous system. Central diabetic neuropathy is a new concept which could be detected by a simple and non-invasive method, called brainstem auditory evoked potential (BAEP). AIM: The aim of the study was to find differences in BAEP latencies of a diabetic patient with good and poor glycemic control. METHODS: This was a cross-sectional study of 80 patients who came for follow-up in diabetic center and neurology polyclinic at Sanglah Hospital, from April to July 2016. The subjects were divided into two groups, depending on their glycemic control, then having BAEP examination. RESULTS: The unpaired t-test found prolonged BAEP latencies (either peak latency of wave III, V, IPL I-III, III-V, and I-V) in both ears at the poor glycemic control group, but the results were not differed significantly (p &gt; 0.05). CONCLUSION: BAEP wave latencies were found prolonged in DM patient with poor glycemic control but not statistically significant. Further evaluation of BAEP latencies in DM patients is needed with prolonged duration and their relation with other comorbid factors, especially smoking habit

The Difference of Brainstem Auditory Evoked Potential Latency in Diabetic Patient with Good and Poor Glycemic Control

BACKGROUND: Diabetes mellitus (DM) is a metabolic disorder which may complicate other organs, including the nervous system. Literatures which discuss about DM complications in the peripheral nervous system are easy to find but not so many of the central nervous system. Central diabetic neuropathy is a new concept which could be detected by a simple and non-invasive method, called brainstem auditory evoked potential (BAEP).&#x0D; AIM: The aim of the study was to find differences in BAEP latencies of a diabetic patient with good and poor glycemic control.&#x0D; METHODS: This was a cross-sectional study of 80 patients who came for follow-up in diabetic center and neurology polyclinic at Sanglah Hospital, from April to July 2016. The subjects were divided into two groups, depending on their glycemic control, then having BAEP examination.&#x0D; RESULTS: The unpaired t-test found prolonged BAEP latencies (either peak latency of wave III, V, IPL I-III, III-V, and I-V) in both ears at the poor glycemic control group, but the results were not differed significantly (p &gt; 0.05).&#x0D; CONCLUSION: BAEP wave latencies were found prolonged in DM patient with poor glycemic control but not statistically significant. Further evaluation of BAEP latencies in DM patients is needed with prolonged duration and their relation with other comorbid factors, especially smoking habit.</jats:p

Differences in Spatial Memory Impairment in Mice after Oral D-Galactose Administration and Intraperitoneal Injection

BACKGROUND: The aging process can increase the incidence of dementia, such as spatial memory impairment to remember space, recognize shapes and distances. Research on dementia in mice was carried out by administering d-galactose through intraperitoneal injection, while oral d-galactose administration had not received enough attention.&#x0D; AIM: This study aims to prove the differences in the occurrence of spatial memory impairment in rats induced by d-galactose through two different routes, oral and intraperitoneal injection.&#x0D; METHODS: This study is an experimental study using a post- test control group design. The sample criteria were 20 male Wistar rats aged 12–14 weeks, weighing 200–300 g divided into two groups which are the oral and intraperitoneal injection. Spatial memory assessment based on spontaneous alternation using the Y-maze test was carried out at the end of week 8.&#x0D; RESULTS: In this study, the average spatial memory score after d-galactose administration in the injection group (51.572±4.388) was lower compared to the oral group (66.058±1.551). The Shapiro–Wilk normality test shows that the data are normally distributed with p &gt; 0.05. Independent t-test showed a significant difference in the incidence of spatial memory disorders between the injection and oral groups with p = 0.010 (p &lt; 0.05).&#x0D; CONCLUSION: The conclusion of this study is that d-galactose administration by oral route or intraperitoneal injection causes a decrease in spatial memory in mice. Spatial memory in the injection group was lower than in the oral group. This might be related to the decrease in synaptophysin in the hippocampus of mice due to d-galactose administration by intraperitoneal injection.</jats:p

Clinical differentiation of psychogenic non-epileptic seizure: a practical diagnostic approach

Abstract Background Psychogenic non-epileptic seizure (PNES) has long been the counterpart of epileptic seizure (ES). Despite ample of evidence differentiating the two, PNES mistakenly diagnosed as ES was still common, resulting in unnecessary exposure to long-term antiepileptic medications and reduced patient’s and caregiver’s quality of life, not to mention the burgeoning financial costs. Objectives In this review, we aimed to elucidate various differences between PNES and epileptic seizure with respect to baseline characteristics, seizure semiology, EEG pattern, and other key hallmark features. Methods An unstructured search was carried out in PubMed, MEDLINE, and EMBASE using keywords pertinent to PNES and ES differentiation. Relevant information was subsequently summarized herein. Results PNES differs significantly with ES in terms of baseline characteristics, prodromal symptoms, seizure semiology, presence of pseudosleep, and other hallmark features (for instance provoking seizure with suggestion). The combined approach, if applied appropriately, can yield high diagnostic yield. Conclusions PNES can be clearly differentiated from ES via careful adherence to a set of valid clinical cues. The summarized clinical hallmarks is highly useful to prevent unnecessary ES diagnosis and treatment with AEDs. </jats:sec

Neurologic manifestations of COVID-19 infection in Asia: a systematic review

AbstractBackgroundCOVID-19 infection can show various manifestation, including neurologic manifestations, such asanosmia,ageusia, ordysgeusia, and causes the neurologic disorder such as stroke, Guillain-Barre syndrome, encephalopathy, and many more.AimTo briefly review neurologic manifestation in COVID-19 infection in the Asia region (South East Asia and the Western Pacific Region).Material and methodsThis review uses the PRISMA statement and checklist. The source for reviewed article was performed in PubMed that were published between December 2019 to September 2020 with the latest 1 year of publication. Study titles were first screened, then reviewed by title and abstract and then the last review, we tested full text and applied eligibility criteria.ResultsWe found a total of 9 retrieved articles from the electronic database. Among these 9 articles, 5 of them are case report, 1 case series, 1 prospective multi-center cohort study, 1 retrospective multi-center study, and 1 retrospective observational study. All articles reported confirmed COVID-19, confirmation by positive swab test using the real-time RT-PCR method, with neurologic manifestations, disorder, or syndrome on presentation or found during hospital stay. In case of neurologic disorder or syndrome, the studies reported encephalitis and ADEM, acute cerebrovascular disease, acute symptomatic seizure, and Guillain-Barré syndrome with acute cerebrovascular disease as the most common neurologic disorder associated with COVID-19 infection, followed by encephalitis.ConclusionCOVID-19 also affects the brain, which may result in a global or focal neurologic manifestation. Healthcare provider treating patient with COVID-19 infection should also be aware of neurologic manifestation associated with COVID-19 infection to improve patient’s outcome.Guillain-Barre syndrome, encephalopathy, and many more. This review will briefly review neurologic manifestation in COVID-19 infection in the Asian region (South East Asia and the Western Pacific Region. A total of 9 retrieved articles from the electronic database reported confirmed COVID-19, confirmation by RT-PCR method, with neurologic manifestation, disorder, or syndrome on presentation or found during hospital stay. Healthcare provider treating patient with COVID-19 infection should also be aware of neurologic manifestation associated with COVID-19 infection to improve patient’s outcome.</jats:sec